VX1+

The VX1+ system is a software-based medical device utilizing machine and deep learning algorithms to assist clinicians in real-time identification and annotation of spatiotemporally dispersed electrograms within 3D atrial maps during atrial fibrillation or tachycardia procedures. Its methodology involves processing intra-cardiac signals to highlight these complex electrical patterns, offering both manual and automatic tagging capabilities, though its direct impact on guiding catheter ablation clinical outcomes is yet to be established.

The Volta Medical VX1+ is a cardiac mapping system designed to assist operators in identifying complex atrial electrical activity during procedures for atrial fibrillation or atrial tachycardia. It employs a machine and deep learning-based algorithm to analyze multipolar intra-cardiac atrial electrograms in real-time. The system's primary function is to help annotate 3D anatomical and electrical maps of the human atria by highlighting areas exhibiting spatiotemporal dispersion, referred to as dispersed electrograms (DEs). The VX1+ operates as a non-sterile, reusable medical device consisting of a computing platform and specialized software, interfacing with standard electrophysiology catheters and compatible data acquisition systems. The VX1+ system processes either analog intra-cardiac signals from EP recording systems or digital signals (including 3D electrode positions) from 3D mapping systems like the Abbott EnSite X. Its output identifies the presence or absence of electrogram dispersion and provides cycle length estimations, with results graphically displayed. A key enhancement over its predicate (VX1) is the capability for bidirectional digital communication, enabling automatic tagging of DE regions directly onto the 3D map when used with compatible systems. While non-clinical tests confirmed the algorithm's correlation with expert analysis and usability, and a small clinical study indicated reliable detection and auto-tagging of DEs without increased risk or procedure time, the document explicitly states that the clinical significance of using VX1+ to guide catheter ablation for atrial arrhythmias has not yet been established by clinical investigations.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the VX1+ algorithm define and quantify "spatiotemporal dispersion," and what are the specific machine learning features it utilizes for this detection?; What is the sensitivity and specificity of the VX1+ automatic annotation feature for identifying clinically relevant dispersed electrograms compared to expert manual annotation across diverse patient populations and arrhythmia types?; Given that the clinical significance for guiding ablation is not yet established, what specific trial designs would be necessary to determine if targeting VX1+-identified dispersed electrograms improves long-term outcomes in atrial fibrillation ablation?; How does the integration of VX1+ with the EnSite X 3D mapping system, particularly the automatic tagging feature, impact procedural workflow and decision-making compared to manual annotation or using the VX1+ with other EP recording systems?; Beyond identifying dispersion, could the machine learning capabilities of VX1+ be expanded to predict other electrophysiological phenomena or guide different aspects of arrhythmia treatment?